Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
1 evidence topic · 1 source
Deramiocel (CAP-1002)
Duchenne muscular dystrophy
- Manufacturer
- Capricor Therapeutics
- Regulatory submission
- Class 2 BLA resubmission submitted February 2026
- Launch
- Not announced
- Last updated